Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia

Nawid Albinger,Rita Pfeifer,Marcus Nitsche,Sarah Mertlitz,Julia Campe,Katja Stein,Hermann Kreyenberg,Ralf Schubert,Melissa Quadflieg,Dina Schneider,Michael W. M. Kühn,Olaf Penack,Congcong Zhang,Nina Möker,Evelyn Ullrich
DOI: https://doi.org/10.1038/s41408-022-00660-2
IF: 9.812
2022-04-01
Blood Cancer Journal
Abstract:Abstract Acute myeloid leukemia (AML) is a malignant disorder derived from neoplastic myeloid progenitor cells characterized by abnormal proliferation and differentiation. Although novel therapeutics have recently been introduced, AML remains a therapeutic challenge with insufficient cure rates. In the last years, immune-directed therapies such as chimeric antigen receptor (CAR)-T cells were introduced, which showed outstanding clinical activity against B-cell malignancies including acute lymphoblastic leukemia (ALL). However, the application of CAR-T cells appears to be challenging due to the enormous molecular heterogeneity of the disease and potential long-term suppression of hematopoiesis. Here we report on the generation of CD33-targeted CAR-modified natural killer (NK) cells by transduction of blood-derived primary NK cells using baboon envelope pseudotyped lentiviral vectors (BaEV-LVs). Transduced cells displayed stable CAR-expression, unimpeded proliferation, and increased cytotoxic activity against CD33-positive OCI-AML2 and primary AML cells in vitro. Furthermore, CD33-CAR-NK cells strongly reduced leukemic burden and prevented bone marrow engraftment of leukemic cells in OCI-AML2 xenograft mouse models without observable side effects.
oncology,hematology
What problem does this paper attempt to address?